Log in
Sign up
Amgen

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company founded in 1980 with headquarters in Thousand Oaks, California.

OverviewStructured DataIssuesContributorsActivity
Contents

Amgen works in discovery, development and manufacturing of human therapeutics for treatment of illnesses in the areas of oncology, hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Products

Amgen’s products include the following: Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine)and Aimovig.

The top protein-based therapeutics include Neulasta, Neupogen, Aranesp, Epogen and Enbrel. ENBREL is on the market in the United States to treat rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. Neulasta treats people receiving chemotherapy to reduce infection. Aranesp and EPOGEN are used to treat anemia in different circumstances including chronic kidney disease. Cinacalcet (Sensipar in US and Mimpara in Europe) is used for secondary hyperparathyroidism with chronic kidney disease. XGEVA is for prevention of skeletal related events in patients with bone metastases from solid tumors. Prolia is used to treat postmenopausal women with osteoporosis at risk of fracture . NEUPOGEN is a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF) to reduce chance of infection due to low white blood cell count for cancer patients receiving chemotherapy . Aimovig was FDA approved in 2018 and will be marketed in partnership with Novartis as a drug to prevent migraines .

Clinical Trials

The following Amgen therapeutics are candidates in Phase III clinical trials: Erenumab for episodic migraine; Aranesp for myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for psoriatic arthritis and rheumatoid arthritis remission; IMLYGIC for metastatic melanoma; Kyprolis for multiple myeloma; Prolia for glucocorticoid-induced osteoporosis; Repatha for hyperlipidemia; XGEVA for delay or prevention of bone metastases in breast cancer and also for the treatment of cancer-related bone damage in patients with multiple myeloma; Vectibix for metastatic colorectal cancer (mCRC); Omecamtiv mecarbil for chronic heart failure, and EVENITY for postmenopausal osteoporosis and male osteoporosis.

The following Amgen therapeutics are candidates in Phase II clinical trials: BLINCYTO for diffuse Large B-Cell Lymphoma (DLBCL) and relapsed/refractory Philadelphia positive (R/R Ph+) and minimal residual disease of ALL; Erenumab for Chronic migraine; AMG 157 for asthma and atopic dermatitis; AMG 520 for Alzheimer's disease, and AMG 899 for dyslipidemia.

The following Amgen therapeutics are candidates in Phase I clinical trials: IMLYGIC for various cancer types; KYPROLIS for small-cell lung cancer; Oprozomib for multiple myeloma; AMG 176 for various cancer types; AMG 211 for various cancer types; AMG 224 for multiple myeloma, and AMG 301 for migraine. The Company's product candidates in Phase I also include AMG 330 for acute myeloid leukemia; AMG 420 for multiple myeloma; AMG 557 for systemic lupus erythematosus; AMG 570 for systemic lupus erythematosus; AMG 592 for inflammatory diseases; AMG 820 for various cancer types, and AMG 986 for heart failure.

Autoimmune disease

The approved drug Otezla (apremilast), acquired from Celgene in 2019, is a notable therapeutic in Amgen’s autoimmune portfolio. Otezla is for treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.

Amgen is partnered with EVOQ Therapeutics for license and collaboration to discover and develop drugs for autoimmune disorders.

Timeline

No Timeline data yet.

Funding Rounds

Open in Query Tool

Products

Open in Query Tool

Acquisitions

Open in Query Tool

SBIR/STTR Awards

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date

Amgen featured in Nasdaq's 2021 Innovation Realized Series

https://youtu.be/YX7DnGZQcxc

Web

November 3, 2021

Fast Facts About the Regulatory Approval Pathway for Biosimilars - Amgen Science

https://youtu.be/ayZ6sjeBURI

Web

January 4, 2022

References

amgen.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biology
Biology
Biotechnology
Biotechnology
Biomedical engineering
Biomedical engineering
Advanced Manufacturing
Advanced Manufacturing
Environmental, social and corporate governance
Environmental, social and corporate governance
Alzheimer's disease
Alzheimer's disease
Healthcare
Healthcare
Diagnosis
Diagnosis
...
Location
Newbury Park, California
Newbury Park, California
Thousand Oaks, California
Thousand Oaks, California
-1
Burnaby
Burnaby
Cambridge, Massachusetts
Cambridge, Massachusetts
Woburn, Massachusetts
Woburn, Massachusetts
West Greenwich, Rhode Island
West Greenwich, Rhode Island
Mississauga
Mississauga
South San Francisco, California
South San Francisco, California
...
B2X
B2B
B2B
CEO
Robert A. Bradway
Robert A. Bradway
-1
Founder
George Rathmann
George Rathmann
AngelList URL
angel.co/amgen
Pitchbook URL
pitchbook.com/profiles.../11108-71
Legal Name
Amgen Limited
Subsidiary
Amgen Ventures
Amgen Ventures
Immunex
Immunex
DGI Resolution, Inc.
DGI Resolution, Inc.
Legal classification
Public company
Public company
Date Incorporated
April 8, 1980
Number of Employees (Ranges)
10,001+-1
Number of Employees
24,200-1
Full Address
One Amgen Center Drive Thousand Oaks, CA 91320-1799
1 Amgen Center Dr Bldg 22 103, Newbury Park, California, 91320, United States-1
1 Health Plz, East Hanover, New Jersey, 07936, United States-1
CIK Number
318,154
Place of Incorporation
Delaware
Delaware
Investors
Ridgeback Capital
Ridgeback Capital
DUNS Number
039976196
IRS Number
953,540,776
Founded Date
1980
Email Address
amgen@careers.pure.cloud-1
accountspayableinquiry@amgen.com-1
investor.relations@amgen.com-1
privacyoffice@amgen.com-1
Phone Number
+18446267526-1
+18884362735-1
+18008676677-1
+18054473505-1
+18054477744-1
+18662642778-1
+18887626436-1
+18883765574-1
...
Competitors
AVA Biochem
AVA Biochem
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
-1
Gilead Sciences
Gilead Sciences
-1
Biogen
Biogen
-1
Adagio Therapeutics
Adagio Therapeutics
Roche
Roche
Stock Symbol
AMGN-1
4332.HK
Exchange
Nasdaq
Nasdaq
-1
Hong Kong Stock Exchange
Hong Kong Stock Exchange
Glassdoor ID
E1130
Board of Directors
‌
Ronald D. Sugar
-1
Charles M. Holley
Charles M. Holley
-1
‌
Amy E. Miles
-1
‌
R. Sanders Williams
-1
Robert A. Bradway
Robert A. Bradway
-1
Ellen J. Kullman
Ellen J. Kullman
-1
Greg Garland
Greg Garland
-1
‌
Robert A. Eckert
-1
...
CFO
‌
Peter Griffith (businessman)
-1
Key People
‌
Jonathan Graham
-1
Robert A. Bradway
Robert A. Bradway
-1
‌
Mike Zahigian
-1
‌
Darryl Sleep
-1
‌
Peter Griffith (businessman)
-1
‌
Victoria H. Blatter
-1
‌
Rizwan Sharnez
‌
Esteban Santos
-1
...
Also Known As
Amgen Inc.
NAICS Code
325,414
CAGE Code
0JVZ6
Patents Assigned (Count)
1,083
Legal Entity Identifier
62QBXGPJ34PQ72Z12S66-1
Motto/Tagline
22 000
Wellfound ID
amgen
Country
United States
United States
-1
Japan
Japan
Canada
Canada
Headquarters
Thousand Oaks, California
Thousand Oaks, California
-1

Other attributes

Blog
amgenbiotechexperience.com/b...og
Company Operating Status
Active
SIC Code
2,836
Wikidata ID
Q470517

Find more companies like Amgen

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.